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Pharmacy Law Brief:

The Federal False Claims Act
Author: Joseph L. Fink III, B.S.Pharm., J.D., Professor of Pharmacy Law and Policy and Kentucky Pharmacists Association Professor of Leadership, Department of Pharmacy Practice and Science, UK College of Pharmacy
Question:
I continually see mention of a federal law
known as the Federal False Claims Act and, in association
with that, read strange phrases and words such as “Quit
Tam Action” and “Relator.” What is all that?

Submit Questions: jfink@uky.edu
Disclaimer:
The information in this column is intended
for educational use and to stimulate professional discussion among colleagues. It should not be construed as legal
advice. There is no way such a brief discussion of an issue
or topic for educational or discussion purposes can adequately and fully address the multifaceted and often complex issues that arise in the course of professional practice. It is always the best advice for a pharmacist to seek
counsel from an attorney who can become thoroughly familiar with the intricacies of a specific situation, and render
advice in accordance with the full information.

Response:
The Federal False Claims Act (FCA) is a
federal statute that creates potential criminal and civil liability for those who would defraud the federal government.
This can apply either to individuals or to companies. The
contemporary statute traces its origins to the Civil War
when a variety of vendors sold defective or adulterated
products to the federal government. Enactment of this statute during the administration of President Lincoln has resulted in this sometimes being referred to as the “Lincoln
Law.” It can be found at 31 U.S.C. §3729.
One unusual feature of the statute is that it permits or authorizes individuals having no affiliation with the federal
government to initiate legal actions on behalf of the government when they have knowledge of nefarious activities that
might run afoul of the law. These people are sometimes
referred to as “whistleblowers” and the resultant filings are
called whistleblower lawsuits.

time. During the Civil War the transgressions that first led to
enactment of the statute primarily related to sales of materiel to the federal government for prosecuting the war. That
focus on military-related purchase continued for quite some
time. In fact, during World War II the statute was enacted to
reduce the share of proceeds directed to the relator. Up
through the 1980s the activities of defense contractors continued to be a principle focus of FCA-related activities. It is
noteworthy, however, that by the late 1990s that focus had
shifted to health care fraud. It is reported that false claims
related to provision of health care goods and services now
comprise a majority of cases filed under the statute.

If the lawsuit is successful the person who filed the suit,
referred to by the title “relator,” can be rewarded with 15-30
percent of the amount recovered. This provision authorizing
an individual to file the lawsuit on behalf of the federal government and creating the entitlement to a portion of the
amount recovered is called the qui tam provision. Those
two words are a key portion of a long legal phrase in Latin
that essentially means “he who sues in this matter for the The pharmaceutical industry, pharmacy chains and individual pharmacies have all come under scrutiny using the Fedking as well as for himself.”
eral False Claims Act. During recent years GlaxoSmithKline
Two of the key provisions in the False Claims Act serve to
entered into a $750 million settlement with federal governprohibit [1] knowingly presenting, or causing to be presentment under the False Claims Act and Ranbaxy Pharmaceued, a false claim for approval or payment, and [2] knowingly
ticals paid a $500 million settlement, both for allegedly remaking, using or causing to be made or used, a false recleasing adulterated medications into interstate commerce.
ord or statement materials to a false or fraudulent claim. So
The Department of Justice reports that the pharmaceutical
either making the false claim or crafting documents to justiindustry was one of the largest contributors to settlements,
fy or support that false submission can run afoul of the law.
with the predominant violation being alleged off-label proIt should be borne in mind that the statute mandates treble
motional activities. Advent of Part D of Medicare with more
damages plus the court can impose additional penalties of
direct, expanded federal payment for pharmaceuticals and
between $5,500 and $11,000 per false claim.
pharmacy services has increased potential exposure in this
There have been interesting shifts with the statute over area.
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Between 2009 and 2012 the federal government recovered
$9.5 billion under this statute. In FY 2013 alone the U.S. Department of Justice recovered $3.8 billion in civil settlements
and judgments under the FCA. Of that total, $2.9 billion was
recovered through qui tam actions. There were 752 qui tam
actions filed during FY 2013, over 100 more than during the
previous year.
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